Gregory Winter, who developed the first technology for making humanised antibodies, has accepted a position as non-executive director at Biosceptre, a therapeutic antibody company developing treatments for cancer. Mr Winter has been chair of the company’s scientific advisory board since 2011 and will help oversee the clinical development of its candidate products targeting the nfP2x7 receptor.
Mr Winter is Master of Trinity College Cambridge and until recently, was a member of the Medical Research Council’s Laboratory of Molecular Biology.
Biosceptre announced the appointment on 31 May 2016.
Copyright 2016 Evernow Publishing Ltd